Atlas market file · Equity · United States
BIO-TECHNE CorpTECH
- Last close
- 71.9
- Change
- -0.14%
- 96-bar range
- 43.2 – 72.37
- As of
- 6 Aug 2026
BIO-TECHNE Corp is a biological products, (no diagnostic substances) issuer listed as TECH on NASDAQ. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
TECH
Equity · evidence first
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 104 weekly closes (-0.54% over the window).
Source rail: Yahoo Finance chart API (TECH). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for TECH. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
Atlas Pro artifact
TECH Market Snapshot PDF
The latest snapshot audit passed. Atlas checks entitlement and evidence again when the PDF is requested.
Atlas Pro entitlement required. The release gate runs again when you request the file.
TECH public profile
Biological products, (no diagnostic substances) issuer. BIO-TECHNE Corp is connected to current market context, cited company sources and its retained research file.
BIO-TECHNE Corp trades as TECH on NASDAQ. BIO-TECHNE Corp (TECH) has a latest verified close of 71.9, down 0.14%, dated 6 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. Atlas files TECH under USA Stocks for browsing.
What changed for BIO-TECHNE Corp today
Bio-Techne Corporation has been making waves with its latest merger agreement with Merck KGaA, a deal that hinges on hitting ambitious revenue and EBITDA milestones. The agreement, filed on June 25, 2026, outlines a two-part forward contract tied to Wilson Wolf’s performance, with the second part triggering if the company achieves $226 million in annual revenue or $136 million in EBITDA (source: Agreement and Plan of Merger, https://www.sec.gov/Archives/edgar/data/842023/000199937126013527/ex2-1.htm).
Bio-Techne is a life sciences company specialising in providing tools for researchers in the biotechnology and pharmaceutical industries. The company’s core business revolves around developing and distributing high-quality reagents, instruments, and services that are essential for scientific research and development. This focus on innovation and quality has positioned Bio-Techne as a key player in the life sciences sector.
The company’s financials offer a mixed picture. Revenue for the quarter ending March 31, 2026, stood at $311.4 million, with net income attributable to the parent company at $51.0 million (source: SEC EDGAR 10-Q, https://www.sec.gov/Archives/edgar/data/842023/000110465926056302/tech-20260331x10q.htm). Operating income was reported at $75.5 million, and cash and cash equivalents at $209.8 million. However, the company’s inventory has been growing, with a $12.5 million increase in the quarter, raising questions about demand and supply chain management.
For those tracking Bio-Techne’s stock, the TradingView chart (https://www.tradingview.com/symbols/NASDAQ-TECH/) provides a visual representation of the company’s market performance. The source directs readers to keep an eye on the company’s ability to meet its merger milestones and manage its inventory levels, as these factors will be crucial in determining its future prospects.
Sources & evidence · 10 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
TECH technical readout
Directional bias up. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on TECH
FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep TECH research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
TECH FAQ
What is BIO-TECHNE Corp (TECH)?BIO-TECHNE Corp (TECH) has a latest verified close of 71.9, down 0.14%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed...
BIO-TECHNE Corp (TECH) has a latest verified close of 71.9, down 0.14%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for TECH?BIO-TECHNE Corp (TECH) has a latest verified close of 71.9, down 0.14%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources, risks...
BIO-TECHNE Corp (TECH) has a latest verified close of 71.9, down 0.14%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. Atlas files TECH under USA Stocks for browsing.
How often is the TECH page updated?The TECH public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The TECH public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for TECH?The TECH file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:TECH. SEC EDGAR provides the filing anchor for this issuer. The page separates...
The TECH file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:TECH. SEC EDGAR provides the filing anchor for this issuer. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on TECH?Yes. The workstation can open TECH, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open TECH, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this TECH page investment advice?No. The TECH page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The TECH page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →